Mutations in the APC/β-catenin genes, which results in aberrant activation of the β-catenin/Tcf-4 pathway, are common in CRC, suggesting that targeted inhibition of this pathway could be a potential therapeutic approach to control CRC. This evidence concerns the gene TCF4 and colorectal carcinoma.